Biomissile Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Biomissile Pharmaceuticals Co., Ltd. is a clinical-stage biotech company dedicated to developing fully human domain antibodies (UDAB) based multi-specific antibodies (UDAB-M) to treat solid tumor, autoimmune, and infectious diseases.
Currently, three projects are in clinical development (Phase I and II), while several others are in pre-clinical stage.
Corporate Highlight:
- Founded in 2020, total capital raised USD $55M.
- Our proprietary UDAB-M platform develops multispecific molecules that selectively activate NK / T cells and IL15 to target cold tumors, including TAA-low and ADC-resistant solid tumors.
- In addition to oncology, UDAB-M NK engagers have been successfully expanded into autoimmune diseases, demonstrating superior B cell depletion compared to T cell engagers (TCE) and Rituximab.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}